UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,768 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 3.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,416 shares of the technology company’s stock after selling 1,768 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.23% of Simulations Plus worth $1,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its stake in shares of Simulations Plus by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after buying an additional 37,992 shares in the last quarter. Tributary Capital Management LLC lifted its stake in shares of Simulations Plus by 54.7% during the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock valued at $10,425,000 after buying an additional 115,122 shares in the last quarter. Royce & Associates LP lifted its stake in shares of Simulations Plus by 28.8% during the 3rd quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock valued at $7,602,000 after buying an additional 53,092 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Simulations Plus by 5.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,317 shares of the technology company’s stock valued at $10,809,000 after buying an additional 11,048 shares in the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of Simulations Plus by 22.5% during the 3rd quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock valued at $6,613,000 after buying an additional 37,914 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Stock Down 0.2 %

Shares of SLP stock opened at $30.88 on Tuesday. The stock has a market cap of $619.67 million, a PE ratio of 63.02 and a beta of 0.76. The business has a 50-day simple moving average of $30.80 and a 200-day simple moving average of $36.24. Simulations Plus, Inc. has a 52-week low of $27.07 and a 52-week high of $51.22.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The company had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the prior year, the firm posted $0.18 EPS. Simulations Plus’s quarterly revenue was up 19.9% compared to the same quarter last year. Sell-side analysts anticipate that Simulations Plus, Inc. will post 1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $27.66, for a total value of $553,200.00. Following the sale, the director now directly owns 3,462,584 shares in the company, valued at $95,775,073.44. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 60,750 shares of company stock worth $1,837,255. Company insiders own 20.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on SLP. Stephens began coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. BTIG Research decreased their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $51.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.